
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences is developing innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to provide cost-effective and precise visualization of liver conditions, particularly Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). The potential FDA approval within the next year is anticipated to drive the stock price significantly higher, supported by a net present value (NPV) analysis indicating substantial upside from the current share price. Additionally, the TAEUS system's capability to enable earlier diagnosis and more accurate monitoring of liver diseases enhances its attractiveness as a transformative tool in the medical diagnostics market.
Bears say
ENDRA Life Sciences Inc. reported a net loss of $1.6 million, translating to an earnings per share (EPS) of $(2.10), which exceeded prior forecasts of $(1.95). The company's financial metrics revealed ongoing challenges, as a subsequent quarter also posted a loss of $1.2 million and an EPS of $(1.71), against estimates of $(2.27). Furthermore, substantial risks were identified, including liquidity concerns, regulatory approval hurdles, commercialization issues, and shifting investor sentiment in the biotech/medtech sectors, all contributing to a fundamentally negative outlook on the stock.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares